Results 41 to 50 of about 6,658 (202)

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

Cancer Management and Research, 2022
Brian W Labadie,1 David S Morris,2 Alan H Bryce,3 Robert Given,4,5 Jingsong Zhang,6 Wassim Abida,7 Simon Chowdhury,8,9 Akash Patnaik1 1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA; 2Urology Associates, P.
Labadie BW, Morris DS, Bryce AH, Given R, Zhang J, Abida W, Chowdhury S, Patnaik A   +7 more
doaj  

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer

EBioMedicine, 2020
Background: Homologous recombination deficiencies (HRD) are present in approximately half of epithelial ovarian cancers, for which PARP inhibitors (PARPi) are becoming a preferred treatment option.
Goldie Y.L. Lui, Reid Shaw, Franz X. Schaub, Isabella N. Stork, Kay E. Gurley, Caroline Bridgwater, Robert L. Diaz, Rachele Rosati, Hallie A. Swan, Tan A. Ince, Thomas C. Harding, Vijayakrishna K. Gadi, Barbara A. Goff, Christopher J. Kemp, Elizabeth M. Swisher, Carla Grandori   +15 more
doaj   +1 more source

A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration

Current Oncology, 2022
PARP inhibitors, such as rucaparib, have been well characterized in metastatic castration-resistant prostate cancer (mCRPC) associated with BRCA alterations, and the clinical activity of these agents has also been evaluated in patients with mCRPC ...
Brieuc Sautois, Andrea Loehr, Simon P. Watkins, Hélène Schroeder, Wassim Abida   +4 more
doaj   +1 more source

Bipolar Androgen Therapy as a Potential Mechanistic Bridge to Enhance PARP Inhibitor Efficacy in Prostate Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Prostate cancer remains a leading cause of cancer‐related mortality, largely driven by progression to metastatic castration‐resistant prostate cancer (mCRPC). Although poly(ADP‐ribose) polymerase inhibitors (PARPis) have improved outcomes in patients with homologous recombination repair (HRR) alterations, particularly in BRCA2‐mutated disease,
Jhen‐Hao Jhan, Jiun‐Hung Geng, Hung‐Lung Ke, Shu‐Pin Huang, Li Jia   +4 more
wiley   +1 more source

AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma

Medicinal Research Reviews, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo, Kaeun Chae, Jueun Lee, Inseon Kim, Seunghun S. Lee   +4 more
wiley   +1 more source

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki, Jennifer La, Danne C. Elbers, Nhan V. Do, Channing J. Paller, Nathanael R. Fillmore, Martin W. Schoen   +6 more
wiley   +1 more source

Rucaparib Approved for Ovarian Cancer [PDF]

Cancer Discovery, 2017
Abstract The FDA approved the PARP inhibitor rucaparib to treat women with advanced ovarian cancer who have already been treated with at least two chemotherapies and have a BRCA1 or BRCA2 gene mutation identified by an approved companion diagnostic test.
openaire   +2 more sources

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Attenuation of Tumor Burden in Response to Rucaparib in Lung Adenocarcinoma: The Contribution of Oxidative Stress, Apoptosis, and DNA Damage

, 2023
In cancer, overactivation of poly (ADPribose) polymerases (PARP) plays a relevant role in DNA repair. We hypothesized that treatment with the PARP inhibitor rucaparib may reduce tumor burden via several biological mechanisms (apoptosis and oxidative ...
Yélamos, José, Blanca León-González, Esther Barreiro, Xavier Duran, Valentí-Serra, Paula, Paula Valentí-Serra, Ampurdanés, Coral, Duran, Xavier, Maria Pérez-Peiró, Barreiro Portela, Esther, Pérez-Peiró, Maria, José Yélamos, Coral Ampurdanés, León-González, Blanca, Barreiro, Esther   +14 more
core   +1 more source